B2BROKER
8.2.2024 09:28:35 CET | Business Wire | Press release
B2Broker, a global powerhouse of liquidity and technology in the B2B sector for crypto, Forex and financial sectors, has partnered with Tools for Brokers (TFB), which provides elite solutions to brokers, liquidity providers, prop trading agencies and hedge funds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208106794/en/
B2Broker partners with Tools for Brokers to integrate Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides. (Graphic: Business Wire)
B2Broker aims to integrate TFB’s Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides.
Importance of B2Broker and TFB Partnership
This collaboration combines B2Broker’s robust liquidity services with TFB’s cutting-edge Trade Processor technology. Here’s what you can expect from the partnership:
Enhanced Risk Mitigation - Trade Processor liquidity gateway introduces the trade routing feature that significantly elevates risk management capabilities for B2Broker clients. The platform can also provide advanced trade routing solutions to retail brokers with their MT4/MT5 servers. Traders can also seamlessly switch between A-Book and B-Book, increasing their flexibility and ability to adapt to market trends.
Elevated Access - With this integration, B2Broker clients will seamlessly access MT4, MT5 and cTrader platforms. The external FIX API integration is also possible for connecting third-party platforms.
Intuitive UI and Advanced Analytics - the Trade Processor also streamlines the digital user interface, making it easy to obtain essential data and access B2Broker’s features. The trading History page now overviews closed positions and all relevant details. Additional pages allow clients to analyse open position stats and exposure metrics and monitor the server performance.
Arthur Azizov, CEO of B2Broker, shared his thoughts on the partnership: "Our collaboration with Tools for Brokers directly supports our goal to deliver innovative technology to clients. TFB's Trade Processor upgrades our offerings with improved risk management and seamless integration across major trading platforms. At the same time, this partnership opens up B2Broker's extensive liquidity pool of over 800 pairs across eight asset classes to TFB users. It’s a mutual exchange of strengths that promises to enhance the value we, B2Broker and TFB, aim to deliver to our clients."
Alexey Kutsenko, the CEO at Tools for Brokers, outlined his excitement for the upcoming collaboration: “We are excited to partner with B2Broker. The company is well-known for its powerful ecosystem of products for brokers. I am confident that together we will create an even stronger solution for B2Brokers’ clients and help them grow faster and stay resilient.”
About Tools for Brokers
Tools for Brokers (TFB) is a global tech provider that serves retail brokers, LPs, prop trading firms and hedge funds operating on multiple platforms like MT4, MT5, Match-Trader and cTrader. TFB’s solutions are powered by their cutting-edge Trade Processor liquidity bridge. The core technology is further elevated by data analytics, risk mitigation tools, money management solutions and a single digital hub to manage TFB plugins effortlessly.
For more information, visit www.t4b.com
B2Broker’s Services
B2Broker is a global leader in the liquidity and fintech sector. B2Broker provides B2B services to forex brokers, crypto exchange platforms, prop traders, crypto spot brokers, multi-asset brokers and many other industries. B2Broker offers over 800 liquidity instruments supported by eight different asset classes. Moreover, the platform features payment processing solutions, white-label solutions, back-office, and numerous other mechanisms to create a full-stop liquidity and business management service for their B2B clients.
For more information, visit b2broker.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208106794/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom